TABLE 2.

Statistical comparisons of steady-state PK parameters of tenofovir, saquinavir, and ritonavir after administration of tenofovir DF and ritonavir-boosted saquinavir alone and in combination^a

Parameterb	TFV PK				SQV PK				RTV PK
	Geometric least-squares means		GMR (%)	90% CI	Geometric least-squares means		GMR (%)	90% CI	Geometric least-squares means		GMR (%)	90% CI
	TDF at 300 mg QD + SQV/r at 1,000/100 mg BID (n = 35)	TDF at 300 mg QD (n = 35)			SQV/r at 1,000/100 mg BID + TDF at 300 mg QD (n = 32)	SQV/r at 1,000/100 mg BID (n = 32)			SQV/r at 1,000/100 mg BID + TDF 300 mg QD (n = 32)	SQV/r at 1,000/100 mg BID (n = 32)
Cmax (ng/ml or μg/ml)*	327	285	114.5	107.4-122.1	2.664	2.184	122.0	105.5-141.0	2.278	2.068	110.1	95.0-127.6
Ctau (ng/ml or μg/ml)*c	68	55	122.5	115.8-129.6	0.591	0.402	147.1	122.6-176.4	0.394	0.321	122.6	103.3-145.6
AUCtau (ng·h/ml or μg·h/ml)*	3,031	2,669	113.5	108.6-118.7	17.306	13.467	128.5	111.8-147.7	12.008	10.841	110.8	100.4-122.2

^aAUC_tau, area under the concentration versus time curve over the dosing interval; BID, twice a day; CI, confidence interval; C_max, maximum observed concentration of drug; C_tau, observed drug concentration at the end of the dosing interval; GMR, geometric least-squares means ratio; QD, once a day; RTV, ritonavir; SQV, saquinavir; SQV/r, ritonavir-boosted saquinavir; TDF, tenofovir disoproxil fumarate; TFV, tenofovir.

^bSee Table 1, footnote b.

^cn = 34.